ENDRA LIFE SCIENCES INC (NDRA)
US29273B3024 - Common Stock
NDRA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for NDRA as it has an excellent financial health rating, but there are worries on the profitability. NDRA has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
NDRA had negative earnings in the past year.
NDRA had a negative operating cash flow in the past year.
NDRA had negative earnings in each of the past 5 years.
NDRA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -105.24%, NDRA is not doing good in the industry: 83.96% of the companies in the same industry are doing better.
The Return On Equity of NDRA (-133.52%) is worse than 69.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -105.24% | ||
| ROE | -133.52% | ||
| ROIC | N/A |
ROA(3y)-126.44%
ROA(5y)-152.36%
ROE(3y)-155.37%
ROE(5y)-200.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for NDRA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for NDRA has been reduced compared to 1 year ago.
NDRA has less shares outstanding than it did 5 years ago.
The debt/assets ratio for NDRA is higher compared to a year ago.
2.2 Solvency
NDRA has an Altman-Z score of -18.13. This is a bad value and indicates that NDRA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NDRA (-18.13) is worse than 86.63% of its industry peers.
There is no outstanding debt for NDRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.13 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 6.10 indicates that NDRA has no problem at all paying its short term obligations.
NDRA has a Current ratio of 6.10. This is amongst the best in the industry. NDRA outperforms 82.35% of its industry peers.
A Quick Ratio of 6.10 indicates that NDRA has no problem at all paying its short term obligations.
NDRA has a Quick ratio of 6.10. This is amongst the best in the industry. NDRA outperforms 86.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.1 | ||
| Quick Ratio | 6.1 |
3. Growth
3.1 Past
The earnings per share for NDRA have decreased strongly by -346.35% in the last year.
EPS 1Y (TTM)-346.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
NDRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.15% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.51%
EPS Next 2Y35.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
NDRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NDRA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NDRA's earnings are expected to grow with 35.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.15%
EPS Next 3YN/A
5. Dividend
5.1 Amount
NDRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ENDRA LIFE SCIENCES INC
NASDAQ:NDRA (12/23/2024, 4:13:03 PM)
After market: 5.41 -0.19 (-3.39%)5.6
+0.09 (+1.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0.09%
Inst Owner Change-39.47%
Ins Owners0.02%
Ins Owner Change0%
Market Cap3.02M
Analysts82.86
Price Target357 (6275%)
Short Float %N/A
Short Ratio0.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)36.47%
Min EPS beat(2)-12.04%
Max EPS beat(2)84.99%
EPS beat(4)3
Avg EPS beat(4)41.23%
Min EPS beat(4)-12.04%
Max EPS beat(4)86.38%
EPS beat(8)6
Avg EPS beat(8)25.66%
EPS beat(12)9
Avg EPS beat(12)18.3%
EPS beat(16)12
Avg EPS beat(16)17.69%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-12.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-18778.8%
EPS NY rev (1m)87.76%
EPS NY rev (3m)-312.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.46 | ||
| P/tB | 0.46 | ||
| EV/EBITDA | N/A |
EPS(TTM)-607.04
EYN/A
EPS(NY)-15.69
Fwd EYN/A
FCF(TTM)-14.97
FCFYN/A
OCF(TTM)-14.93
OCFYN/A
SpS0
BVpS12.23
TBVpS12.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -105.24% | ||
| ROE | -133.52% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-126.44%
ROA(5y)-152.36%
ROE(3y)-155.37%
ROE(5y)-200.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 33.57% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.1 | ||
| Quick Ratio | 6.1 | ||
| Altman-Z | -18.13 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)89.68%
Cap/Depr(5y)79.81%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-346.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.3%
EPS Next Y46.51%
EPS Next 2Y35.15%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.6%
OCF growth 3YN/A
OCF growth 5YN/A